Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al.
Burstein
Sumner
S
Zurier
Robert B
RB
D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D001169:Arthritis, Experimental / Q000188:drug therapy; D002185:Cannabidiol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004195:Disease Models, Animal; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D010146:Pain / Q000188:drug therapy*; D011619:Psychotropic Drugs
D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003509:Cyclohexanecarboxylic Acids; C483300:HU 320; D011619:Psychotropic Drugs; D002185:Cannabidiol; D013759:Dronabinol; C471849:lenabasum